Cardioprotective Effect of Metformin on the level of micro RNAs, mir-222, mir-195, mir-21a, in type 1 diabetes patients

Phase 2

Conditions: Condition 1: Type 1 diabetes. Condition 2: Cardiovascular disease.

Registration Number: IRCT20200217046520N1

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 28

Inclusion Criteria

age 19 to 45 years
insulin-treated
for the past three months the patient's blood sugar has been controlled
HbA1c ranged from 6/5 to 7/5
lack of cardiovascular disease
it's been 5 years since diabetes
informed consent

Exclusion Criteria

pregnancy or pregnancy intent in the near future
Kidney failure (creatinine equal to or greater than 1/3)
history of cardiovascular disease
history of intraocular injection
Glycated haemoglobin greater than 7/5

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma levels of micro RNA 222 before and after metformin administration. Timepoint: Plasma level of micro RNA 222 at baseline and 12 weeks after metformin administration. Method of measurement: blood test.;Plasma levels of micro RNA 195 before and after metformin administration. Timepoint: Plasma level of micro RNA 195 at baseline and 12 weeks after metformin administration. Method of measurement: blood test.;Plasma levels of micro RNA 21a before and after metformin administration. Timepoint: Plasma level of micro RNA 21a at baseline and 12 weeks after metformin administration. Method of measurement: blood test.

Secondary Outcome Measures